Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
Clinical trial NCT00046683 · COMPLETED
Trial details
- NCT number
- NCT00046683
- Sponsor
- Genzyme, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2001-07-01
- Enrollment
- 284
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.